Search International and National Patent Collections

1. (WO2017037573) PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER

Pub. No.:    WO/2017/037573    International Application No.:    PCT/IB2016/055041
Publication Date: Fri Mar 10 00:59:59 CET 2017 International Filing Date: Thu Aug 25 01:59:59 CEST 2016
IPC: A61K 31/4439
A61K 31/506
A61P 35/00
Applicants: NOVARTIS AG
CAPONIGRO, Giordano
HORN-SPIROHN, Thomas
LEHAR, Joseph
Inventors: CAPONIGRO, Giordano
HORN-SPIROHN, Thomas
LEHAR, Joseph
Title: PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER
Abstract:
The present disclosure pertains to a pharmaceutical combination comprising (a) alpha- isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.